TrialRespiratory research2017

Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population.

Leif Bjermer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.